Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Barry Kahan

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Procedures

Chemicals & Drugs

Physiology

Living Beings

Anatomy

Kidney

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
99
Van Buren, Charles
98
Stepkowski, Stanislaw
71
Kerman, Ronald
31
Katz, Stephen
28
Napoli, Kimberly
27
Wang, Min
27
Wang, Mou-Er
23
Tian, Ling
21
Podder, Hemangshu
19
Schoenberg, Linda
19
Katz, Stephen
17
Kimball, Pam
16
Yu, J
14
Qu, Xuimei
13
Tejpal, Neelam

Sign-in to see all Coauthors

Publications

TOP 3
Kahan B D
Current approaches to the use of sirolimus in renal transplantation.
Kahan Barry D
Forty years of publication of transplantation proceedings--the second decade: the cyclosporine revolution.
Taylor A; Kahan B D
Living donor kidney transplantation without transmission of multiple sclerosis after 10 years.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Barry Kahan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Kahan B D
Current approaches to the use of sirolimus in renal transplantation.
Transplantation proceedings 2009;41(8):3011-5.
2009: Kahan Barry D
Forty years of publication of transplantation proceedings--the second decade: the cyclosporine revolution.
Transplantation proceedings 2009;41(5):1423-37.
2009: Taylor A; Kahan B D
Living donor kidney transplantation without transmission of multiple sclerosis after 10 years.
Clinical nephrology 2009;71(4):454-5.
2009: Kahan B D
The ruby anniversary: forty years of publication of Transplantation Proceedings - the first decade: the flowering of immunology and immunogenetics.
Transplantation proceedings 2009;41(1):5-10.
2009: Kaposztas Z; Podder H; Mauiyyedi S; Illoh O; Kerman R; Reyes M; Pollard V; Kahan B D
Impact of rituximab therapy for treatment of acute humoral rejection.
Clinical transplantation 2009;23(1):63-73.
2008: Kahan B D
Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.
Transplantation proceedings 2008;40(10 Suppl):S17-20.
2008: Gaber A Osama; Kahan Barry D; Van Buren Charles; Schulman Seth L; Scarola Joseph; Neylan John F;
Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Transplantation 2008;86(9):1187-95.
2008: Knight R J; Kerman R H; McKissick E; Lawless A; Podder H; Katz S; Van Buren C T; Kahan B D
Selective corticosteroid and calcineurin-inhibitor withdrawal after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy.
Clinical transplantation 2008;22(5):645-50.
2008: Kaposztas Z; Etheridge W B; Kahan B D
Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus.
Transplantation proceedings 2008;40(5):1744-6.
2008: Kahan B D; Podbielski J; Childs B
The impact of conversion from mycophenolate mofetil to mycophenolate sodium among renal transplant recipients on a sirolimus-based regimen.
Transplantation proceedings 2008;40(5):1429-34.
2008: Burke James T; Brault Yves; Kahan Barry D; Hricik Donald E; Grinyó Josep M; Chapman Jeremy R; Polinsky Martin; Neylan John F
Accuracy and variability of equations to estimate glomerular filtration rates in renal transplant patients receiving sirolimus and/or calcineurin inhibitor immunosuppression.
Transplant international : official journal of the European Society for Organ Transplantation 2008;21(5):434-40.
2008: Kahan B D
Frontiers in immunosuppression.
Transplantation proceedings 2008;40(1):11-5.
2007: Lisik W; Schoenberg L; Lasky R E; Kahan B D
Statins benefit outcomes of renal transplant recipients on a sirolimus-cyclosporine regimen.
Transplantation proceedings 2007;39(10):3086-92.
2007: Langer Róbert; Tóth András; Máthé Zsolt; Remport Adám; Járay Jeno; Kahan Barry D
[Lymphocele and kidney transplantation]
Orvosi hetilap 2007;148(31):1475-80.
2007: Knight Richard J; Villa Martin; Laskey Robert; Benavides Carlos; Schoenberg Linda; Welsh Maria; Kerman Ronald H; Podder Hemangshu; Van Buren Charles T; Katz Stephen M; Kahan Barry D
Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients.
Clinical transplantation 2007;21(4):460-5.
2007: Benavides Carlos A; Pollard Vida B; Mauiyyedi Shamila; Podder Hemangshu; Knight Richard; Kahan Barry D
BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes.
Transplantation 2007;84(1):83-8.
2007: Kobayashi Katsuhiro; Censullo Michael L; Rossman Lucho L; Kyriakides Polina N; Kahan Barry D; Cohen Alan M
Interventional radiologic management of renal transplant dysfunction: indications, limitations, and technical considerations.
Radiographics : a review publication of the Radiological Society of North America, Inc 2007;27(4):1109-30.
2007: Kahan Barry D
Losing the kingdom: the case against commercial organ donation.
Nature clinical practice. Urology 2007;4(6):290-1.
2006: Kahan B D; Podbielski J; Schoenberg L
Use of sirolimus to facilitate steroid withdrawal from a cyclosporine regimen.
Transplantation proceedings 2006;38(9):2842-6.
2006: Knight R J; Kahan B D
The place of sirolimus in kidney transplantation: can we reduce calcineurin inhibitor renal toxicity?
Kidney international 2006;70(6):994-9.
2006: Benavides C A; Csapo Z; Timmins K; Holley L; Katz S M; Van Buren C T; Kahan B D
Fibromuscular dysplasia recurrence after kidney transplantation: case report.
Clinical nephrology 2006;66(1):67-70.
2006: Csapo Zsolt; Knight Richard J; Podder Hemangshu; Kerman Ronald H; Schoenberg Linda; Katz Stephen M; Van Buren Charles T; Kahan Barry D
Long-term outcomes of single paediatric vs. ideal adult renal allograft transplants in adult recipients.
Clinical transplantation 2006;20(4):423-6.
2006: Knight Richard J; Kerman Ronald H; Zela Scott; Podbielski Jeannette; Podder Hemangshu; Van Buren Charles T; Katz Stephen; Kahan Barry D
Pancreas transplantation utilizing thymoglobulin, sirolimus, and cyclosporine.
Transplantation 2006;81(8):1101-5.
2006: Yakupoglu Y K; Buell J F; Woodle S; Kahan B D
Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy.
Transplantation proceedings 2006;38(2):358-61.
2006: Lisik W; Kahan B D
Individualization of immunosuppressive therapy. II. Sirolimus as a less nephrotoxic alternative to calcineurin inhibitors.
Transplantation proceedings 2006;38(1):69-73.
2006: Zhang Ye; Kirken Robert A; Furian Lucrezia; Janczewska Slawa; Qu Xiumei; Hancock Wayne W; Wang Mouer; Tejpal Neelam; Kerman Ronald; Kahan Barry D; Stepkowski Stanislaw M
Allograft rejection requires STAT5a/b-regulated antiapoptotic activity in T cells but not B cells.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(1):128-37.
2006: Kahan Barry D; Podder Herman
Anesthetic rejection followed by surgical salvage.
Clinical transplants 2006;():572-3.
2006: Podder Herman; Kerman Ronald H; Illoh Orieji C; Kahan Barry D
Sickle cell disease: a formidable enemy of the transplanter.
Clinical transplants 2006;():570-1.
2005: Hong M E; Hong J C; Stepkowski S; Kahan B D
Correlation between cyclosporine-induced nephrotoxicity in reduced nephron mass and expression of kidney injury molecule-1 and aquaporin-2 gene.
Transplantation proceedings 2005;37(10):4254-8.
2005: Podder H; Kahan B D
Individualization of immunosuppressive therapy: I. Sirolimus improves outcomes in African-American renal transplant recipients.
Transplantation proceedings 2005;37(9):3723-6.
2005: Knight R J; Kerman R H; McKissick E; Lawless A; Podder H; Katz S; Van Buren C T; Kahan B D
A pilot study of immunosuppression minimization after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy.
Transplantation proceedings 2005;37(8):3538-41.
2005: Stepkowski Stanislaw M; Kao Judy; Wang Mou-Er; Tejpal Neelam; Podder Hemangshu; Furian Lucrezia; Dimmock Jonathan; Jha Amitabh; Das Umashankar; Kahan Barry D; Kirken Robert A
The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(7):4236-46.
2005: Kahan Barry D; Yakupoglu Yarkin K; Schoenberg Linda; Knight Richard J; Katz Stephen M; Lai Deijan; Van Buren Charles T
Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients.
Transplantation 2005;80(6):749-58.
2005: Csapo Z; Benavides-Viveros C; Podder H; Pollard V; Kahan B D
Campath-1H as rescue therapy for the treatment of acute rejection in kidney transplant patients.
Transplantation proceedings 2005;37(5):2032-6.
2005: Knight R J; Kerman R H; Podder H; Katz S M; Van Buren C T; Kahan B D
Graft survival and immune regulation of pancreas allograft recipients induced with thymoglobulin, sirolimus, and cyclosporine.
Transplantation proceedings 2005;37(2):1280-2.
2005: Benavides C; Mahmoud K H; Knight R; Barcenas C; Kahan B D; Van Buren C T
Rabbit antithymocyte globulin: a postoperative risk factor for sirolimus-treated renal transplant patients?
Transplantation proceedings 2005;37(2):822-6.
2005: Csapo Z; Knight R J; Podder H; Kerman R H; Schoenberg L; Katz S M; Van Buren C T; Kahan B D
Transplantation of single pediatric kidneys into adult recipients.
Transplantation proceedings 2005;37(2):697-8.
2004: Podder Hemangshu; Kahan Barry D
Janus kinase 3: a novel target for selective transplant immunosupression.
Expert opinion on therapeutic targets 2004;8(6):613-29.
2004: Kahan Barry D
Sirolimus-based immunosuppression: present state of the art.
Journal of nephrology 2004;17 Suppl 8():S32-9.
2004: Langer Robert; Wang Mouer; Stepkowski Stanislaw M; Hancock Wayne W; Han Rongxiang; Li Ping; Feng Lily; Kirken Robert A; Berens Kurt L; Dupre Brian; Podder Hemangshu; Dixon Richard A F; Kahan Barry D
Selectin inhibitor bimosiamose prolongs survival of kidney allografts by reduction in intragraft production of cytokines and chemokines.
Journal of the American Society of Nephrology : JASN 2004;15(11):2893-901.
2004: Knight Richard J; Kerman Ronald H; Schoenberg Linda; Podder Hemangshu; Van Buren Charles T; Katz Stephen; Kahan Barry D
The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function.
Transplantation 2004;78(6):904-10.
2004: Kahan Barry D; Stepkowski Stanislaw; Kilic Murat; Katz Steven M; Van Buren Charles T; Welsh Maria S; Tami Joseph A; Shanahan William R
Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection.
Transplantation 2004;78(6):858-63.
2004: Knight R J; Zela S; Schoenberg L; Podder H; Kerman R H; Katz S; Van Buren C T; Kahan B D
The effect of pancreas transplantation on peripheral vascular disease complications.
Transplantation proceedings 2004;36(4):1069-71.
2004: Kahan B D
FTY720: from bench to bedside.
Transplantation proceedings 2004;36(2 Suppl):531S-543S.
2004: Kahan B D
Therapeutic drug monitoring of cyclosporine: 20 years of progress.
Transplantation proceedings 2004;36(2 Suppl):378S-391S.
2004: Kahan B D
Sirolimus: a ten-year perspective.
Transplantation proceedings 2004;36(1):71-5.
2003: Perez John; Stepkowski Stanislaw M; Song Ping; Trawick Barton; Wang Mou-Er; Janczewska Slawa; Kahan Barry D
Selection of lowly immunogenic and highly tolerogenic donor and recipient allochimeric class I major histocompatibility complex proteins.
Transplantation 2003;76(8):1201-7.
2003: Kahan Barry D; Karlix Janet L; Ferguson Ronald M; Leichtman Alan B; Mulgaonkar Shamkant; Gonwa Thomas A; Skerjanec Andrej; Schmouder Robert L; Chodoff Lawrence
Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study.
Transplantation 2003;76(7):1079-84.
2003: Kahan Barry D
Individuality: the barrier to optimal immunosuppression.
Nature reviews. Immunology 2003;3(10):831-8.
2003: Kahan B D
The emerging matrix of immunosuppressive agents.
Transplantation proceedings 2003;35(6):2365-8.
2003: Kahan B D; Kirken R A; Stepkowski S M
New approaches to transplant immunosuppression.
Transplantation proceedings 2003;35(5):1621-3.
2003: Chueh Shih-Chieh J; Kahan Barry D
Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis.
Transplantation 2003;76(2):375-82.
2003: Aki Fazil Tuncay; Kahan Barry D
FTY720: A new kid on the block for transplant immunosuppression.
Expert opinion on biological therapy 2003;3(4):665-81.
2003: Yakupoglu Yarkin K; Kahan Barry D
Sirolimus: a current perspective.
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2003;1(1):8-18.
2003: Kahan B D
Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation.
Transplantation proceedings 2003;35(3 Suppl):37S-51S.
2003: Kahan B D; Knight R; Schoenberg L; Pobielski J; Kerman R H; Mahalati K; Yakupoglu Y; Aki F T; Katz S; Van Buren C T
Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience.
Transplantation proceedings 2003;35(3 Suppl):25S-34S.
2003: Knight Richard J; Kerman Ronald H; Zela Scott; Podder Hemangshu; Van Buren Charles T; Katz Stephen; Kahan Barry D
Thymoglobulin, sirolimus, and reduced-dose cyclosporine provides excellent rejection prophylaxis for pancreas transplantation.
Transplantation 2003;75(8):1301-6.
2002: Kahan B D
Sirolimus and FTY720: new approaches to transplant immunosuppression.
Transplantation proceedings 2002;34(7):2520-2.
2002: Langer Robert M; Kahan Barry D
Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients.
Transplantation 2002;74(6):804-8.
2002: Langer R M; Kahan B D
Alexis Carrel's legacy: visionary of vascular surgery and organ transplantation.
Transplantation proceedings 2002;34(4):1061-6.
2002: Stepkowski Stanislaw M; Kirken Robert A; Trawick Barton W; Wang Min; Tejpal Neelam; Wang Mou-Er; Tian Ling; Clark James; Kahan Barry D
Allochimeric class I MHC protein-induced tolerance by partial TCR engagement requires activation of both CTL4- and common gamma-chain-dependent cytokine signals.
Transplantation 2002;73(8):1227-35.
2002: Langer R M; Kahan Barry D
100 years ago: Ullmann's pioneering operation--autotransplantation of the kidney.
Transplantation proceedings 2002;34(2):429-33.
2002: Kahan Barry D; Keown Paul; Levy Gary A; Johnston Atholl
Therapeutic drug monitoring of immunosuppressant drugs in clinical practice.
Clinical therapeutics 2002;24(3):330-50; discussion 329.
2002: Kovarik John M; Kaplan Bruce; Tedesco Silva Hélio; Kahan Barry D; Dantal Jacque; Vitko Stefan; Boger Robert; Rordorf Christiane
Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range.
Transplantation 2002;73(6):920-5.
2002: Langer Robert M; Van Buren Charles T; Katz Stephen M; Kahan Barry D
De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination.
Transplantation 2002;73(5):756-60.
2002: Kahan B D
The limitations of calcineurin and mTOR inhibitors: new directions for immunosuppressive strategies.
Transplantation proceedings 2002;34(1):130-3.
2002: Kahan Barry D
Update on pharmacokinetic/pharmacodynamic studies with FTY720 and sirolimus.
Therapeutic drug monitoring 2002;24(1):47-52.
2002: Stepkowski Stanislaw M; Erwin-Cohen Rebecca A; Behbod Fariba; Wang Mou-Er; Qu Xienui; Tejpal Neelam; Nagy Zsuzsanna S; Kahan Barry D; Kirken Robert A
Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin.
Blood 2002;99(2):680-9.
2001: Kahan B D
Sirolimus: a comprehensive review.
Expert opinion on pharmacotherapy 2001;2(11):1903-17.
2001: Stepkowski S M; Kirken R A; Nagy Z S; Trawick B W; Wang M; Tejpal N; Wang M E; Tian L; Clark J; Kahan B D
The role of Stat5 in the induction of regulatory T cells in transplantation tolerance.
Transplantation proceedings 2001;33(7-8):3835-6.
2001: Stepkowski S M; Nagy Z S; Kahan B D; Kirken R A
The role of signals 1, 2, and 3 in induction of transplantation tolerance.
Transplantation proceedings 2001;33(7-8):3831-2.
2001: Stepkowski S M; Chen W; Bennett C F; Condon T P; Stecker K; Tian L; Kahan B D
Phosphorothioate/methoxyethyl-modified ICAM-1 antisense oligonucleotides improves prevention of ischemic/reperfusion injury.
Transplantation proceedings 2001;33(7-8):3705-6.
2001: Stepkowski S M; Nagy Z S; Wang M E; Behbod F; Erwin-Cohen R; Kahan B D; Kirken R A
PNU156804 inhibits Jak3 tyrosine kinase and rat heart allograft rejection.
Transplantation proceedings 2001;33(7-8):3272-3.
2001: Langer R M; Van Buren C T; Katz S M; Kahan B D
De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine a sirolimus combination.
Transplantation proceedings 2001;33(7-8):3236-7.
2001: Mahalati K; Kahan B D
A pilot study of steroid withdrawal from kidney transplant recipients on sirolimus-cyclosporine a combination therapy.
Transplantation proceedings 2001;33(7-8):3232-3.
2001: Kahan B D
The evolution of therapeutic drug monitoring of cyclosporine.
Transplantation proceedings 2001;33(7-8):3086-8.
2001: Kahan B D
FTY720: a new dimension in transplantation.
Transplantation proceedings 2001;33(7-8):3081-3.
2001: Kahan B D
The matrix of clinical immunosuppression for transplantation.
Transplantation proceedings 2001;33(7-8):3035-7.
2001: Kahan B D; Camardo J S
Rapamycin: clinical results and future opportunities.
Transplantation 2001;72(7):1181-93.
2001: Kahan B D; Koch S M
Current immunosuppressant regimens: considerations for critical care.
Current opinion in critical care 2001;7(4):242-50.
2001: Kahan B D; Kramer W G
Median effect analysis of efficacy versus adverse effects of immunosuppressants.
Clinical pharmacology and therapeutics 2001;70(1):74-81.
2001: Kahan B D
Potential therapeutic interventions to avoid or treat chronic allograft dysfunction.
Transplantation 2001;71(11 Suppl):SS52-7.
2001: Podder H; Podbielski J; Hussein I; Katz S; Van Buren C; Kahan B D
Sirolimus improves the two-year outcome of renal allografts in African-American patients.
Transplant international : official journal of the European Society for Organ Transplantation 2001;14(3):135-42.
2001: Hong J C; Kahan B D
Sirolimus rescue therapy for refractory rejection in renal transplantation.
Transplantation 2001;71(11):1579-84.
2001: Hong J C; Kahan B D
A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function.
Transplantation 2001;71(9):1320-8.
2001: Kahan B D; Kaplan B; Lorber M I; Winkler M; Cambon N; Boger R S
RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection.
Transplantation 2001;71(10):1400-6.
2001: Podder H; Stepkowski S M; Napoli K L; Clark J; Verani R R; Chou T C; Kahan B D
Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations.
Journal of the American Society of Nephrology : JASN 2001;12(5):1059-71.
2001: Behbod F; Erwin-Cohen R A; Wang M E; Trawick B W; Qu X; Verani R; Kahan B D; Stepkowski S M; Kirken R A
Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts.
Journal of immunology (Baltimore, Md. : 1950) 2001;166(6):3724-32.
2001: Kahan B D; Napoli K L; Podbielski J; Hussein I; Katz S H; Van Buren C T
Therapeutic drug monitoring of sirolimus for optimal renal transplant outcomes.
Transplantation proceedings 2001;33(1-2):1278.
2001: Hong J C; Kahan B D
A calcineurin antagonist-free induction immunosuppression strategy for delayed graft function in renal transplantation.
Transplantation proceedings 2001;33(1-2):1271-2.
2001: Mahalati K; Kahan B D
Sirolimus permits steroid withdrawal from a cyclosporine regimen.
Transplantation proceedings 2001;33(1-2):1270.
2001: Podder H; Podbielski J; Hussein I; Katz S M; Van Buren C T; Kahan B D
Impact of sirolimus on renal transplant outcomes in African Americans.
Transplantation proceedings 2001;33(1-2):1226.
2001: Podder H; Stepkowski S M; Napoli K; Kahan B D
Pharmacokinetic interactions between sirolimus and cyclosporine exacerbate renal dysfunction.
Transplantation proceedings 2001;33(1-2):1086.
2001: Hong J C; Kahan B D
Sirolimus rescue therapy for refractory rejection in renal transplant recipients.
Transplantation proceedings 2001;33(1-2):1033.
2001: Chen W; Bennett C F; Condon T P; Stecker K; Tian L; Kahan B D; Stepkowski S M
Methoxyethyl modification of phosphorothioate ICAM-1 antisense oligonucleotides improves prevention of ischemic/reperfusion injury.
Transplantation proceedings 2001;33(1-2):854.
2001: Gebel H M; Bray R A; Ruth J A; Zibari G B; McDonald J C; Kahan B D; Kerman R H
Flow PRA to detect clinically relevant HLA antibodies.
Transplantation proceedings 2001;33(1-2):477.
2001: Kerman R H; Katz S M; Van Buren C T; Ruth J; McKissick E; Rasmussen S; Kahan B D
Posttransplant immune monitoring of anti-HLA antibody.
Transplantation proceedings 2001;33(1-2):402.
2001: Kerman R H; Katz S M; Van Buren C T; Garcia C; Kahan B D
Addition of rapamycin to cyclosporine-prednisone based immunosuppression reduces the clinical risk of pretransplant anti-HLA antibody.
Transplantation proceedings 2001;33(1-2):401.
2001: Wang M; Kirken R; Behbod F; Erwin-Cohen R; Stepkowski S M; Kahan B D
Inhibition of Jak3 tyrosine kinase by PNU156804 blocks rat heart allograft rejection.
Transplantation proceedings 2001;33(1-2):201.
2001: Stepkowski S M; Kirken R A; Wang M; Yu J; Akioka K; Kahan B D
Tolerance induction by alteration of T cell receptor (TCR) signaling using an allochimeric donor/recipient class I MHC protein.
Transplantation proceedings 2001;33(1-2):131.
2001: Kirken R A; Erwin-Cohen R; Behbod F; Wang M; Stepkowski S M; Kahan B D
Tyrphostin AG490 selectively inhibits activation of the JAK3/STAT5/MAPK pathway and rejection of rat heart allografts.
Transplantation proceedings 2001;33(1-2):95.
2001: Kovarik J M; Kahan B D; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
Clinical pharmacology and therapeutics 2001;69(1):48-56.
2001: Mahalati K; Kahan B D
Clinical pharmacokinetics of sirolimus.
Clinical pharmacokinetics 2001;40(8):573-85.
2000: Katz S M; Bennett F; Stecker K; Clark J H; Pham T; Wang M E; Kahan B D; Stepkowski S M
ICAM-1 antisense oligodeoxynucleotide improves islet allograft survival and function.
Cell transplantation 2000;9(6):817-28.
2000: Meier-Kriesche H U; Swinford R; Kahan B D; Brannan P; Portman R J
Reduced variability of neoral pharmacokinetic studies in pediatric renal transplantation.
Pediatric nephrology (Berlin, Germany) 2000;15(1-2):2-6.
2000: Okamoto M; Stepkowski S M; Wang M; Kahan B D
Use of allochimeric proteins to mitigate graft-versus-host and host-versus-graft immune responses to rat small bowel allografts.
Transplantation 2000;70(7):1060-7.
2000: Kahan B D
Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group.
Lancet 2000;356(9225):194-202.
2000: Kahan B D; Welsh M; Urbauer D L; Mosheim M B; Beusterien K M; Wood M R; Schoenberg L P; Dicesare J; Katz S M; Van Buren C T
Low intraindividual variability of cyclosporin A exposure reduces chronic rejection incidence and health care costs.
Journal of the American Society of Nephrology : JASN 2000;11(6):1122-31.
2000: Hong J C; Kahan B D
Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management.
Transplantation 2000;69(10):2085-90.
2000: Katz S M; Hong J C; Kahan B D
New immunosuppressive agents.
Transplantation proceedings 2000;32(3):620-1.
2000: Kahan B D; Napoli K L; Kelly P A; Podbielski J; Hussein I; Urbauer D L; Katz S H; Van Buren C T
Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity.
Clinical transplantation 2000;14(2):97-109.
2000: Hong J C; Kahan B D
Immunosuppressive agents in organ transplantation: past, present, and future.
Seminars in nephrology 2000;20(2):108-25.
2000: Yuzawa K; Stephkowski S M; Wang M; Kahan B D
FTY720 blocks allograft rejection by homing of lymphocytes in vivo.
Transplantation proceedings 2000;32(2):269.
2000: Kahan B D; Stepkowski S M; Napoli K L; Katz S M; Knight R J; Van Buren C
The development of sirolimus: The University of Texas-Houston experience.
Clinical transplants 2000;():145-58.
2000: Mahalati K; Kahan B D
Pharmacological surrogates of allograft outcome.
Annals of transplantation : quarterly of the Polish Transplantation Society 2000;5(2):14-23.
1999: Kerman R H; Susskind B; Buyse I; Pryzbylowski P; Ruth J; Warnell S; Gruber S A; Katz S; Van Buren C T; Kahan B D
Flow cytometry-detected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome.
Transplantation 1999;68(12):1855-8.
1999: Meier-Kriesche H U; Bonilla-Felix M A; Ferris M E; Swinford R; Kahan B D; Brannan P; Portman R J
A limited sampling strategy for the estimation of Neoral AUCs in pediatric patients.
Pediatric nephrology (Berlin, Germany) 1999;13(9):742-7.
1999: Kahan B D; Julian B A; Pescovitz M D; Vanrenterghem Y; Neylan J
Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group.
Transplantation 1999;68(10):1526-32.
1999: Akioka K; Kirkin R; Wang M; Tian L; Yu J; Stepkowski S M; Kahan B D
Reduced expression of NF-AT and NF-kappa B transcription factors in tolerant recipients treated with tolerogenic allochimeric donor/recipient class I MHC protein.
Transplantation proceedings 1999;31(7):2745-6.
1999: Kovarik J M; Kahan B D; Rajagopalan P R; Bennett W; Mulloy L L; Gerbeau C; Hall M L
Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group.
Transplantation 1999;68(9):1288-94.
1999: Kahan B D; Wong R L; Carter C; Katz S H; Von Fellenberg J; Van Buren C T; Appel-Dingemanse S
A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients.
Transplantation 1999;68(8):1100-6.
1999: Chen W; Bennett C F; Wang M E; Dragun D; Tian L; Stecker K; Clark J H; Kahan B D; Stepkowski S M
Perfusion of kidneys with unformulated "naked" intercellular adhesion molecule-1 antisense oligodeoxynucleotides prevents ischemic/reperfusion injury.
Transplantation 1999;68(6):880-7.
1999: Hong J C; Kahan B D
Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression.
Transplantation 1999;68(5):701-4.
1999: Kahan B D
The potential role of rapamycin in pediatric transplantation as observed from adult studies.
Pediatric transplantation 1999;3(3):175-80.
1999: Stroehlein K B; Stroehlein J R; Kahan B D; Gruber S A
Gastric mucosal calcinosis in renal transplant patients.
Transplantation proceedings 1999;31(5):2124-6.
1999: Kahan B D
An immunosuppressive triumvirate to minimize renal injuries associated with calcineurin antagonist therapy.
Transplantation 1999;68(1):12-4.
1999: Tian L; Wang M; Yu J; Kahan B D; Stepkowski S M
Nucleotide sequences of three distinct complementary DNA clones encoding rat class II major histocompatibility complex RT1.D beta-chain proteins.
Immunogenetics 1999;49(7-8):735-7.
1999: Kahan B D
Considerations concerning generic formulations of immunosuppressive drugs.
Transplantation proceedings 1999;31(3):1635-41.
1999: Kahan B D
Recommendations concerning the introduction of generic formulations of cyclosporine.
Transplantation proceedings 1999;31(3):1634; discussion 1675-84.
1999: Perez J; Yu J; Stepkowski S M; Kahan B D
Immunization with Escherichia coli-produced soluble MHC class I proteins induces accelerated rejection or prolonged survival of rat cardiac allografts.
Transplantation proceedings 1999;31(3):1560.
1999: Stepkowski S M; Yu J; Wang M; Kahan B D
Induction of tolerance by oral administration of a tolerogenic allochimeric donor/recipient class I MHC protein.
Transplantation proceedings 1999;31(3):1557.
1999: Wang M; Yu J; Stepkowski S M; Kahan B D
Localization of immunogenic and tolerogenic epitopes in the RT1.A1 alloantigen.
Transplantation proceedings 1999;31(3):1517-8.
1999: Clark J; Kerman R; Susskind B; Katz S; Van Buren C; Kahan B
Correlation of pretransplant allosensitization with severity of rejection biopsy.
Transplantation proceedings 1999;31(1-2):751-2.
1999: Kahan B D
Cyclosporine: a revolution in transplantation.
Transplantation proceedings 1999;31(1-2A):14S-15S.
1999: Kaplan B; Meier-Kriesche H U; Napoli K L; Kahan B D
Correlation between pretransplantation test dose cyclosporine pharmacokinetic profiles and posttransplantation sirolimus blood levels in renal transplant recipients.
Therapeutic drug monitoring 1999;21(1):44-9.
1999: Kahan B D; Rajagopalan P R; Hall M
Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group.
Transplantation 1999;67(2):276-84.
1999: Przybylowski P; Balogna M; Radovancevic B; Frazier O H; Susskind B; Van Buren C; Katz S; Kahan B D; Kerman R
The role of flow cytometry-detected IgG and IgM anti-donor antibodies in cardiac allograft recipients.
Transplantation 1999;67(2):258-62.
1999: Troncoso P; Stepkowski S M; Wang M E; Qu X; Chueh S C; Clark J; Kahan B D
Prophylaxis of acute renal allograft rejection using FTY720 in combination with subtherapeutic doses of cyclosporine.
Transplantation 1999;67(1):145-51.
1998: Kerman R H; Susskind B; Ruth J; Katz S; Van Buren C T; Kahan B D
Can an immunologically, nonreactive potential allograft recipient undergo transplantation without a donor-specific crossmatch?
Transplantation 1998;66(12):1833-4.
1998: Susskind B; Kerman R H; Nelson R; Gregory J; La T; Bayat A; Dang M; Van Buren C; Katz S; Kahan B D
Comparison between enzyme-linked immunosorbent assay and cytotoxic cross-match procedures for detecting IgG anti-donor antibodies.
Transplantation 1998;66(12):1823-6.
1998: Kahan B D; Podbielski J; Napoli K L; Katz S M; Meier-Kriesche H U; Van Buren C T
Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation.
Transplantation 1998;66(8):1040-6.
1998: Stepkowski S M; Wang M E; Condon T P; Cheng-Flournoy S; Stecker K; Graham M; Qu X; Tian L; Chen W; Kahan B D; Bennett C F
Protection against allograft rejection with intercellular adhesion molecule-1 antisense oligodeoxynucleotides.
Transplantation 1998;66(6):699-707.
1998: Kerman R H; Susskind B; Kerman D; Lam M; Gerolami K; Williams J; Kalish R; Campbell M; Katz S; Van Buren C T; Frazier H; Radovancevic B; Fife S; Kahan B
Comparison of PRA-STAT, sHLA-EIA, and anti-human globulin-panel reactive antibody to identify alloreactivity in pretransplantation sera of heart transplant recipients: correlation to rejection and posttransplantation coronary artery disease.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 1998;17(8):789-94.
1998: Kahan B D
Renaissance of immunosuppressive therapy in the new millennium.
Transplantation proceedings 1998;30(5):2493-6.
1998: Stepkowski S M; Wang M; Qu X; Yu J; Okamoto M; Tejpal N; Kahan B D
Synergistic interaction of FTY720 with cyclosporine or sirolimus to prolong heart allograft survival.
Transplantation proceedings 1998;30(5):2214-6.
1998: Kahan B D
FTY720: a new immunosuppressive agent with novel mechanism(s) of action.
Transplantation proceedings 1998;30(5):2210-3.
1998: Kahan B D; Napoli K L
Role of therapeutic drug monitoring of rapamycin.
Transplantation proceedings 1998;30(5):2189-91.
1998: Kahan B D
Rapamycin: personal algorithms for use based on 250 treated renal allograft recipients.
Transplantation proceedings 1998;30(5):2185-8.
1998: Kahan B D
High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection.
Transplantation proceedings 1998;30(5):1639-41.
1998: Kahan B D
New dimensions in transplantation--weaving the future.
Transplantation proceedings 1998;30(5):1617-8.
1998: Meier-Kriesche H U; Kaplan B; Brannan P; Kahan B D; Portman R J
A limited sampling strategy for the estimation of eight-hour neoral areas under the curve in renal transplantation.
Therapeutic drug monitoring 1998;20(4):401-7.
1998: Troncoso P; Kahan B D
Preclinical evaluation of a new immunosuppressive agent, FTY720.
Clinical biochemistry 1998;31(5):369-73.
1998: Kahan B D
Emerging strategies for the clinical application of rapamycin.
Clinical biochemistry 1998;31(5):341-4.
1998: Beyga Z T; Kahan B D
Surgical complications of kidney transplantation.
Journal of nephrology 1998;11(3):137-45.
1998: Boyle M J; Baghdassarian V; Stepkowski S M; Dumble L J; Kahan B D
Intrasplenic liver parenchymal cells in conjunction with low-dose rapamycin and cyclosporine induce a unique and specific prolongation of rat cardiac and small bowel allograft survival.
Cell transplantation 1998;7(3):247-56.
1998: Wang M E; Tejpal N; Qu X; Yu J; Okamoto M; Stepkowski S M; Kahan B D
Immunosuppressive effects of FTY720 alone or in combination with cyclosporine and/or sirolimus.
Transplantation 1998;65(7):899-905.
1998: Napoli K L; Wang M E; Stepkowski S M; Kahan B D
Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: evidence for pharmacokinetic interactions.
Therapeutic drug monitoring 1998;20(2):123-33.
1998: Chueh S C; Kahan B D
Pretransplant test-dose pharmacokinetic profiles: cyclosporine microemulsion versus corn oil-based soft gel capsule formulation.
Journal of the American Society of Nephrology : JASN 1998;9(2):297-304.
1998: Kaplan B; Meier-Kriesche H U; Napoli K L; Kahan B D
The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent.
Clinical pharmacology and therapeutics 1998;63(1):48-53.
1998: Senel M F; Van Buren C T; Welsh M; Kahan B D
Impact of early cyclosporin average blood concentration on early kidney transplant failure.
Transplant international : official journal of the European Society for Organ Transplantation 1998;11(1):46-52.
1997: Kelly P A; Gruber S A; Behbod F; Kahan B D
Sirolimus, a new, potent immunosuppressive agent.
Pharmacotherapy 1997;17(6):1148-56.
1997: Chueh S C; Tian L; Wang M; Wang M E; Stepkowski S M; Kahan B D
Induction of tolerance toward rat cardiac allografts by treatment with allochimeric class I MHC antigen and FTY720.
Transplantation 1997;64(10):1407-14.
1997: Tian L; Stepkowski S M; Qu X; Wang M E; Wang M; Yu J; Kahan B D
Cytokine mRNA expression in tolerant heart allografts after immunosuppression with cyclosporine, sirolimus or brequinar.
Transplant immunology 1997;5(3):189-98.
1997: Wang M; Stepkowski S M; Yu J; Wang M; Kahan B D
Localization of cryptic tolerogenic epitopes in the alpha1-helical region of the RT1.Au alloantigen.
Transplantation 1997;63(10):1373-9.
1997: Stepkowski S M; Wang M; Langowski J; Ghobrial R; Qu X; Yu J; Tian L; Kahan B D
Localization of tolerogenic epitopes in the alpha 1 helical region of the rat class I major histocompatibility complex molecule.
Transplantation proceedings 1997;29(3):1663-4.
1997: Wang M; Stepkowski S M; Tian L; Langowski J; Yu J; Kloc M; Kahan B D
Nucleotide sequences of rat cDNA clones coding heavy chain class I major histocompatibility complex proteins.
Transplantation proceedings 1997;29(3):1661-2.
1997: Stepkowski S M; Tian L; Napoli K L; Ghobrial R; Wang M E; Chou T C; Kahan B D
Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection.
Clinical and experimental immunology 1997;108(1):63-8.
1997: Napoli K L; Wang M E; Stepkowski S M; Kahan B D
Distribution of sirolimus in rat tissue.
Clinical biochemistry 1997;30(2):135-42.
1997: Kaplan B; Meier-Kriesche H U; Napoli K; Kahan B D
A limited sampling strategy for estimating sirolimus area-under-the-concentration curve.
Clinical chemistry 1997;43(3):539-40.
1997: Katz S M; Tian L; Stepkowski S M; Phan T; Bennett C F; Kahan B D
Effect of ICAM-1/LFA-1 blockade on pancreatic islet allograft survival, function, and early cytokine production.
Transplantation proceedings 1997;29(1-2):748-9.
1997: Kerman R H; Susskind B; Kerman D H; Lam M; Gerolami K; Williams J; Kalish R; Campbell M; Katz S M; Van Buren C T; Kahan B D
Anti-HLA antibodies detected in posttransplant renal allograft recipient sera correlate with chronic rejection.
Transplantation proceedings 1997;29(1-2):1515-6.
1997: Kerman R H; Susskind B; Slaton J; Lewis R M; Heydari A; Ruth J; Williams J; Van Buren C T; Katz S M; Kahan B D
Improved graft survival in 100 retransplant recipients following AHG-negative crossmatching.
Transplantation proceedings 1997;29(1-2):1451-3.
1997: Kerman R H; Susskind B; Katz S M; Van Buren C T; Kahan B D
Postrenal transplant MLR hypo-responders have fewer rejections and better graft survival than MLR hyper-responders.
Transplantation proceedings 1997;29(1-2):1410-1.
1997: Stepkowski S M; Wang M E; Amante A; Kalinin D; Qu X; Blasdel T; Condon T; Kahan B D; Bennett F C
Antisense ICAM-1 oligonucleotides block allograft rejection in rats.
Transplantation proceedings 1997;29(1-2):1285.
1997: Wang M; Yu J; Wang M E; Tian L; Stepkowski S M; Kahan B D
Induction of donor-specific tolerance by chimeric class I MHC molecules bearing donor alpha 1 helical amino acids.
Transplantation proceedings 1997;29(1-2):1224-5.
1997: Kahan B D
Sirolimus: a new agent for clinical renal transplantation.
Transplantation proceedings 1997;29(1-2):48-50.
1997: Kerman R H; Katz S M; Schoenberg L; Baraket O; Van Buren C T; Kahan B D
Ten-year follow-up of mixed lymphocyte reaction-hyporesponsive living related cyclosporine monotherapy-treated renal allograft recipients.
Transplantation proceedings 1997;29(1-2):198-9.
1997: Stepkowski S M; Tian L; Wang M E; Qu X; Napoli K; Kahan B D
Sirolimus in transplantation.
Archivum immunologiae et therapiae experimentalis 1997;45(5-6):383-90.
1997: Kahan B D
New approaches for the prevention of early graft rejection.
Kidney & blood pressure research 1997;20(3):167-9.
1997: Amante A J; Meier-Kriesche H U; Schoenberg L; Kahan B D
A pharmacokinetic comparison of the corn oil versus microemulsion gelcap formulation of cyclosporin used de novo after renal transplantation.
Transplant international : official journal of the European Society for Organ Transplantation 1997;10(3):217-22.
1996: He G; Wang M; Xu H; Tian L; Yu J; Stepkowski S M; Kahan B D
Impact of different forms of recipient antigen and different routes of antigen administration in donor pretreatment for preventing graft-versus-host disease in rat small bowel transplantation.
Transplantation proceedings 1996;28(5):2469.
1996: Ghobrial R R; Hamashima T; Wang M E; Wang M; Stepkowski S M; Kahan B D
Induction of transplantation tolerance by chimeric donor/recipient class I RT1.Aa molecules.
Transplantation 1996;62(7):1002-10.
1996: Stepkowski S M; Napoli K L; Wang M E; Qu X; Chou T C; Kahan B D
Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats.
Transplantation 1996;62(7):986-94.
1996: Kahan B D; Welsh M; Schoenberg L; Rutzky L P; Katz S M; Urbauer D L; Van Buren C T
Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection.
Transplantation 1996;62(5):599-606.
1996: Kahan B D
Frontiers for the coming millennium.
Transplantation proceedings 1996;28(4):2299-306.
1996: Kahan B D
Case study: de novo application of Neoral in renal transplantation.
Transplantation proceedings 1996;28(4):2189-91; discussion 2192, 2195.
1996: Katz S M; Amante A; Schoenberg L; Kahan B D
Oral cyclosporine preparations immediately following renal transplantation.
Transplantation proceedings 1996;28(4):2164.
1996: Amante A J; Kahan B D
Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period.
Transplantation proceedings 1996;28(4):2162-3.
1996: Kahan B D
Pharmacokinetic considerations in the therapeutic application of cyclosporine in renal transplantation.
Transplantation proceedings 1996;28(4):2143-6.
1996: Kerman R H; Susskind B; Buelow R; Regan J; Pouletty P; Williams J; Gerolami K; Kerman D H; Katz S M; Van Buren C T; Kahan B D
Correlation of ELISA-detected IgG and IgA anti-HLA antibodies in pretransplant sera with renal allograft rejection.
Transplantation 1996;62(2):201-5.
1996: Senel M F; Van Buren C T; Riggs S; Clark J; Etheridge W B; Kahan B D
Post-transplantation lymphoproliferative disorder in the renal transplant ureter.
The Journal of urology 1996;155(6):2025.
1996: Slaton J W; Kahan B D
Case report--sirolimus rescue therapy for refractory renal allograft rejection.
Transplantation 1996;61(6):977-9.
1996: Amante A J; Kahan B D
En bloc transplantation of kidneys from pediatric donors.
The Journal of urology 1996;155(3):852-6; discussion 856-7.
1996: Wang M; Qu X; Stepkowski S M; Chou T C; Kahan B D
Beneficial effect of graft perfusion with anti-T cell receptor monoclonal antibodies on survival of small bowel allografts in rat recipients treated with brequinar alone or in combination with cyclosporine and sirolimus.
Transplantation 1996;61(3):458-64.
1996: Wang M; Stepkowski S M; Wang M E; Tian L; Qu X; Tu Y; He G; Kahan B D
Induction of specific allograft immunity by soluble class I MHC heavy chain protein produced in a baculovirus expression system.
Transplantation 1996;61(3):448-57.
1996: Murgia M G; Jordan S; Kahan B D
The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients.
Kidney international 1996;49(1):209-16.
1996: Senel M F; Van Buren C T; Etheridge W B; Barcenas C; Jammal C; Kahan B D
Effects of cyclosporine, azathioprine and prednisone on Kimura's disease and focal segmental glomerulosclerosis in renal transplant patients.
Clinical nephrology 1996;45(1):18-21.
1996: Susskind B M; Kerman R H; Browne B J; Hartwell B A; Davis B G; Katz S M; Van Buren C T; Kahan B D
The impact of elevated serum IgA and race on primary recipient renal allograft survival.
Transplantation 1996;61(2):205-11.
1996: Wang M; Stepkowski S M; Hebert J S; Tian L; Yu J; Kahan B D
Nucleotide sequences of three H-2K and three H-2D complementary DNA clones coding mouse class I MHC heavy chain proteins.
Annals of transplantation : quarterly of the Polish Transplantation Society 1996;1(3):26-31.
1996: Ghobrial R; Karczewski M; Ferraresso M; Tian L; Stepkowski S M; Kahan B D
Kinetics of in vitro immune responses of T and B cells during tolerance induction by sirolimus.
Annals of transplantation : quarterly of the Polish Transplantation Society 1996;1(4):22-9.
1996: Wang M; Stepkowski S M; Tian L; Langowski J L; Yu J; Kahan B D
Nucleotide sequences of three distinct clones coding for rat heavy chain class I major histocompatibility antigens.
Immunogenetics 1996;43(5):318-20.
1996: Wang M; Stepkowski S M; Tian L; Langowski J L; Hebert J S; Kloc M; Yu J; Kahan B D
Nucleotide sequences of three distinct cDNA clones coding for the rat class I heavy chain RT1n antigen.
Immunogenetics 1996;45(1):73-5.
1995: Hamashima T; Stepkowski S M; Chou T C; Kahan B D
Synergistic interaction of 3 M KCl-extracted donor antigens (e-HAg) with cyclosporine or cyclosporine/sirolimus for prolongation of rat heart allograft survival.
Transplant immunology 1995;3(4):335-41.
1995: Kahan B D; Murgia M G; Slaton J; Napoli K
Potential applications of therapeutic drug monitoring of sirolimus immunosuppression in clinical renal transplantation.
Therapeutic drug monitoring 1995;17(6):672-5.
1995: Kahan B D; Welsh M; Rutzky L P
Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring.
Therapeutic drug monitoring 1995;17(6):621-4.
1995: Kahan B D
The evolution of therapeutic immunosuppression and the potential impact of drug concentration monitoring.
Therapeutic drug monitoring 1995;17(6):560-3.
1995: Katz S M; Browne B; Phan T; Wang M E; Bennett C F; Stepkowski S M; Kahan B D
Efficacy of ICAM-1 antisense oligonucleotide in pancreatic islet transplantation.
Transplantation proceedings 1995;27(6):3214.
1995: Ghobrial R; Hamashima T; Kloc M; Etkin L; Stepkowski S M; Kahan B D
Membrane-bound or soluble truncated RT1.Aa rat class I major histocompatibility antigens induce specific alloimmunity.
Transplantation 1995;60(6):602-10.
1995: Ghobrial R R; Stepkowski S M; Kahan B D
Molecular engineering of the major histocompatibility complex for immunomodulation.
Clinical transplantation 1995;9(3 Pt 2):237-45.
1995: Wang M; Stepkowski S M; Kahan B D
Donor pretreatment with anti-T-cell receptor monoclonal antibodies prevents graft-vs-host disease in brequinar-treated small bowel allograft recipients.
Transplantation proceedings 1995;27(1):383.
1995: Kahan B D
Concentration-controlled immunosuppressive regimens using cyclosporine with sirolimus or brequinar in human renal transplantation.
Transplantation proceedings 1995;27(1):33-6.
1995: Ghobrial R; Hamashima T; Stepkowski S M; Kahan B D
Induction of transplantation tolerance by perioperative injection of "quasi-self" chimeric class I MHC antigen combined with a short cyclosporine course.
Transplantation proceedings 1995;27(1):239-40.
1995: Hamashima T; Stepkowski S M; Kahan B D
Dose-dependent effect of intrathymically injected 3-mol/L KCl-extracted histocompatibility antigens to prolong heart allograft survival in rats.
Transplantation proceedings 1995;27(1):134-5.
1995: Kahan B D; Dunn J; Fitts C; Van Buren D; Wombolt D; Pollak R; Carson R; Alexander J W; Choc M; Wong R
Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals.
Transplantation 1995;59(4):505-11.
1995: Tu Y; Stepkowski S M; Chou T C; Kahan B D
The synergistic effects of cyclosporine, sirolimus, and brequinar on heart allograft survival in mice.
Transplantation 1995;59(2):177-83.
1994: Kahan B D
Concentration control: a key to phase I development of immunosuppressive agents.
Transplantation proceedings 1994;26(6):3203-4.
1994: Ferraresso M; Tian L; Ghobrial R; Stepkowski S M; Kahan B D
Rapamycin inhibits production of cytotoxic but not noncytotoxic antibodies and preferentially activates T helper 2 cells that mediate long-term survival of heart allografts in rats.
Journal of immunology (Baltimore, Md. : 1950) 1994;153(7):3307-18.
1994: Kahan B D
Role of cyclosporine: present and future.
Transplantation proceedings 1994;26(5):3082-7.
1994: Hamashima T; Stepkowski S M; Smith S; Kahan B D
Synergistic effect of 3M KCl-extracted donor antigens with cyclosporine or cyclosporine/rapamycin to prolong heart allograft survival in rats.
Transplantation proceedings 1994;26(5):3053-5.
1994: Stepkowski S M; Tu Y; Chou T C; Kahan B D
Synergistic interactions of cyclosporine, rapamycin, and brequinar on heart allograft survival in mice.
Transplantation proceedings 1994;26(5):3025-7.
1994: Kahan B D; Chou T; Tejpal N; Wang M; Chee C; Stepkowski S
Synergistic effects of cyclosporin analogs--A, D, G, IMM-125--with rapamycin and/or brequinar.
Transplantation proceedings 1994;26(5):3021-4.
1994: Browne B J; Jordan S; Welsh M S; Van Buren C; Kahan B D
Diet and cyclosporin A--pharmacokinetic comparison between Neoral and Sandimmune gelatin capsules.
Transplantation proceedings 1994;26(5):2959-60.
1994: Kerman R H; Kimball P M; Williams J; Heydari A; Cavazos D; Ruth J; Katz S; Ozaki C; Clark J; Kahan B D
Immunoregulatory mechanisms identified in liver transplant recipients.
Transplantation proceedings 1994;26(5):2857-8.
1994: Lewis R; Podbielski J; Munsell M; Katz S; Van Buren C; Kerman R; Kahan B D
Stability of renal allograft glomerular filtration rate in the cyclosporine era: 2-year follow-up.
Transplantation proceedings 1994;26(5):2619-21.
1994: Kahan B D
Toward quantitative theories of immunosuppressive drug action: Averroes and the Arabic and Spanish eras of medicine.
Transplantation proceedings 1994;26(5):2469-74.
1994: Amante A J; Kahan B D
Technical complications of renal transplantation.
The Surgical clinics of North America 1994;74(5):1117-31.
1994: Browne B J; Kahan B D
Renal transplantation.
The Surgical clinics of North America 1994;74(5):1097-116.
1994: Kahan B D; Ghobrial R
Immunosuppressive agents.
The Surgical clinics of North America 1994;74(5):1029-54.
1994: Hamashima T; Stepkowski S M; Smith S; Kahan B D
Induction of transplantation tolerance by a single intrathymic injection of 3M KCl-extracted donor histocompatibility antigens combined with two doses of anti-rat alpha/beta-T cell receptor monoclonal antibodies.
Transplantation 1994;58(1):105-7.
1994: Knight R J; Kurrle R; McClain J; Racenberg J; Baghdahsarian V; Kerman R; Lewis R; van Buren C T; Kahan B D
Clinical evaluation of induction immunosuppression with a murine IgG2b monoclonal antibody (BMA 031) directed toward the human alpha/beta-T cell receptor.
Transplantation 1994;57(11):1581-8.
1994: Knight R J; Kurrle R; Stepkowski S; Serino F; Chou T C; Kahan B D
Synergistic immunosuppressive actions of cyclosporine with a mouse anti-rat alpha/beta-T cell receptor monoclonal antibody.
Transplantation 1994;57(11):1544-8.
1994: Lewis R M; Verani R R; Vo C; Katz S M; Van Buren C T; Radovancevic B; Kerman R H; Frazier O H; Kahan B D
Evaluation of chronic renal disease in heart transplant recipients: importance of pretransplantation native kidney histologic evaluation.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 1994;13(3):376-80.
1994: Kerman R H; Kimball P; Scheinen S; Radovancevic B; Van Buren C T; Kahan B D; Frazier O H
The relationship among donor-recipient HLA mismatches, rejection, and death from coronary artery disease in cardiac transplant recipients.
Transplantation 1994;57(6):884-8.
1994: Napoli K L; Kahan B D
Sample clean-up and high-performance liquid chromatographic techniques for measurement of whole blood rapamycin concentrations.
Journal of chromatography. B, Biomedical applications 1994;654(1):111-20.
1994: Katz S M; Kimball P M; Ozaki C; Monsour H; Clark J; Cavazos D; Kahan B D; Wood R P; Kerman R H
Positive pretransplant crossmatches predict early graft loss in liver allograft recipients.
Transplantation 1994;57(4):616-20.
1994: Kahan B D
New immunosuppressive drugs--pharmacologic approaches to alter immunoregulation.
Therapeutic immunology 1994;1(1):33-44.
1994: Browne B J; Kahan B D
Transplantation 1994: the year in review.
Clinical transplants 1994;():317-40.
1993: Kerman R H; Kimball P M; Lindholm A; Van Buren C T; Katz S M; Lewis R M; McClain J; Podbielski J; Williams J; Kahan B D
Influence of HLA matching on rejections and short- and long-term primary cadaveric allograft survival.
Transplantation 1993;56(5):1242-7.
1993: Ferraresso M; Kahan B D
New immunosuppressive agents for pediatric transplantation.
Pediatric nephrology (Berlin, Germany) 1993;7(5):567-73.
1993: Wang M; Tu Y; Stepkowski S M; Kahan B D
Effect of cyclosporine alone or in combination with rapamycin and brequinar on survival of hamster heart xenograft in rats.
Transplantation proceedings 1993;25(5):2876-7.
1993: Stepkowski S M; Ghobrial R; Wang B; Ito Y; Goto S; Hamashima T; Kahan B D
Donor-soluble histocompatibility antigen selectively potentiates suppressor elements while decreasing the frequency of alloantigen-specific T cytotoxic cells.
Transplantation proceedings 1993;25(5):2875.
1993: Ferraresso M; Rigotti P; Stepkowski S M; Chou T C; Kahan B D
Immunosuppressive effects of defibrotide.
Transplantation 1993;56(4):928-33.
1993: Lindholm A; Kahan B D
Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation.
Clinical pharmacology and therapeutics 1993;54(2):205-18.
1993: Kahan B D
Optimization of cyclosporine therapy.
Transplantation proceedings 1993;25(4 Suppl 3):5-9.
1993: Kerman R H; Kimball P M; Lindholm A; Van Buren C T; Katz S M; Lewis R M; Podbielski J; Williams J; Kahan B D
Immune risk factors: impact on the incidence and diagnosis of rejection.
Transplantation proceedings 1993;25(4 Suppl 3):23-5.
1993: Lewis R M; Podbielski J; Munsell M; Katz S; Van Buren C; Kerman R; Kahan B
Optimization and long-term evaluation of renal function in sandimmune-treated renal allograft recipients.
Transplantation proceedings 1993;25(4 Suppl 3):10-2.
1993: Kahan B D
Timeline of immunosuppression.
Transplantation proceedings 1993;25(4 Suppl 3):1-4.
1993: Stepkowski S M; Kahan B D
Synergistic activity of the triple combination: cyclosporine, rapamycin, and brequinar.
Transplantation proceedings 1993;25(3 Suppl 2):29-31.
1993: Grevel J; Post B K; Kahan B D
Michaelis-Menten kinetics determine cyclosporine steady-state concentrations: a population analysis in kidney transplant patients.
Clinical pharmacology and therapeutics 1993;53(6):651-60.
1993: Lindholm A; Welsh M; Rutzky L; Kahan B D
The adverse impact of high cyclosporine. Clearance rates on the incidences of acute rejection and graft loss.
Transplantation 1993;55(5):985-93.
1993: Dumble L J; Gibbons S; Tejpal N; Chou T C; Redgrave N G; Boyle M J; Kahan B D
15 AU81, a prostacyclin analog, potentiates immunosuppression and mitigates renal injury due to cyclosporine.
Transplantation 1993;55(5):1124-8.
1993: Lewis R; Podbielski J; Sprayberry S; Munsell M; Katz S; Rubin M; Kimball P; Van Buren C T; Kerman R; Kahan B
Stability of renal allograft glomerular filtration rate associated with long-term use of cyclosporine A.
Transplantation 1993;55(5):1014-7.
1993: Kahan B D; Tejpal N; Gibbons-Stubbers S; Tu Y; Wang M; Stepkowski S; Chou T C
The synergistic interactions in vitro and in vivo of brequinar sodium with cyclosporine or rapamycin alone and in triple combination.
Transplantation 1993;55(4):894-900.
1993: Ferraresso M; Ghobrial R; Stepkowski S M; Kahan B D
The mechanism of unresponsiveness to allografts induced by rapamycin and rapamycin/cyclosporine treatment in rats.
Transplantation 1993;55(4):888-94.
1993: Ferraresso M; Wang M E; Stepkowski S M; Kahan B D
Rescue therapy with rapamycin blocks an ongoing process of heart allograft rejection.
Transplantation proceedings 1993;25(1 Pt 1):729.
1993: Kimball P; Kerman R H; Williams J; Kahan B D
Cyclosporine and rapamycin block protein kinase C-mediated induction of the activation signal, activator of DNA replication, in cell-free assay.
Transplantation proceedings 1993;25(1 Pt 1):518-9.
1993: Kahan B D
Cyclosporine: the base for immunosuppressive therapy--present and future.
Transplantation proceedings 1993;25(1 Pt 1):508-10.
1992: Komichi H; Smith S; Kahan B D
Immunotherapy with a tumor-infiltrating lymphocyte clone, soluble antigen, and cyclophosphamide.
Archives of surgery (Chicago, Ill. : 1960) 1992;127(12):1417-23.
1992: Wang M E; Stepkowski S M; Ferraresso M; Kahan B D
Evidence that rapamycin rescue therapy delays rejection of major (MHC) plus minor (non-MHC) histoincompatible heart allografts in rats.
Transplantation 1992;54(4):704-9.
1992: Lindholm A; Welsh M; Alton C; Kahan B D
Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability.
Clinical pharmacology and therapeutics 1992;52(4):359-71.
1992: Lindholm A; Napoli K; Rutzky L; Kahan B D
Specific monoclonal radioimmunoassay and fluorescence polarization immunoassay for trough concentration and area-under-the-curve monitoring of cyclosporine in renal transplantation.
Therapeutic drug monitoring 1992;14(4):292-300.
1992: Kahan B D; Gibbons-Stubber S; Tejpal N; Chou T C
Prospects for synergistic immunosuppressive drug therapy in the coming decade.
Transplantation proceedings 1992;24(4):1263-5.
1992: Kahan B D
Cyclosporin A, FK506, rapamycin: the use of a quantitative analytic tool to discriminate immunosuppressive drug interactions.
Journal of the American Society of Nephrology : JASN 1992;2(12 Suppl):S222-7.
1992: Goto S; Stepkowski S M; Kahan B D
Benefit of multiple over single doses of 3M KCL-extracted histocompatibility antigen in the potentiating cyclosporine-induced prolongation of rat cardiac allograft survival.
Transplantation 1992;53(3):705-7.
1992: Kahan B D; Welsh M; Rutzky L; Lewis R; Knight R; Katz S; Napoli K; Grevel J; Van Buren C T
The ability of pretransplant test-dose pharmacokinetic profiles to reduce early adverse events after renal transplantation.
Transplantation 1992;53(2):345-51.
1992: Stepkowski S M; Chen H F; Wang M E; Daloze P; Kahan B D
Inhibition of host-versus-graft and graft-versus-host responses after small bowel transplantation in rats by rapamycin.
Transplantation 1992;53(2):258-64.
1992: Kerman R H; Kimball P M; Van Buren C T; Lewis R M; Cavazos D; Heydari A; Kahan B D
Influence of race on crossmatch outcome and recipient eligibility for transplantation.
Transplantation 1992;53(1):64-7.
1992: Knight R J; Vathsala A; Schoenberg L; Camel S; Weinberg R B; Goldstein R A; Lewis R M; van Buren C T; Kahan B D
Treatment of hyperlipidemia in renal transplant patients with gemfibrozil and dietary modification.
Transplantation 1992;53(1):224-5.
1992: Kahan B D
New immunosuppressive drugs: needs in and applications to pediatric transplantation.
European journal of pediatrics 1992;151 Suppl 1():S9-12.
1991: Stepkowski S M; Kahan B D
Rapamycin and cyclosporine synergistically prolong heart and kidney allograft survival.
Transplantation proceedings 1991;23(6):3262-4.
1991: Grevel J; Kahan B D
Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy.
Clinical chemistry 1991;37(11):1905-8.
1991: Miyagawa S; Stepkowski S M; Lawen J G; Rutzky L P; Kahan B D
In vitro correlates of in vivo therapy with cyclosporine to immunosuppress rejection of heterotopic rat cardiac allografts across strong (RT-1) plus weak (non-RT-1) histocompatibility differences.
Transplantation 1991;52(5):851-7.
1991: Delhey K; Lewis R; Dunn J; Berry J; Gray R; Van Buren C; Kahan B
Absence of tumor transmission from a cadaveric renal donor with malignant astrocytoma and a ventriculoperitoneal shunt--two-year recipient follow-up and review of the literature.
Transplantation 1991;52(4):737-8.
1991: Napoli K L; Kahan B D
Considerations for monitoring cyclosporine in transplant recipients.
Clinics in laboratory medicine 1991;11(3):671-91.
1991: Kahan B D; Chang J Y; Sehgal S N
Preclinical evaluation of a new potent immunosuppressive agent, rapamycin.
Transplantation 1991;52(2):185-91.
1991: Vathsala A; Goto S; Yoshimura N; Stepkowski S; Chou T C; Kahan B D
The immunosuppressive antagonism of low doses of FK506 and cyclosporine.
Transplantation 1991;52(1):121-8.
1991: Citterio F; Kahan B D
Cyclosporine's dual mechanism of action in inhibiting generation of the cytoplasmic activation signal and the nuclear response thereto.
Transplantation 1991;51(6):1248-57.
1991: Grevel J; Kahan B D
Area under the curve monitoring of cyclosporine therapy: the early posttransplant period.
Therapeutic drug monitoring 1991;13(2):89-95.
1991: Grevel J; Napoli K L; Welsh M S; Atkinson N E; Kahan B D
Prediction of acute graft rejection in renal transplantation: the utility of cyclosporine blood concentrations.
Pharmaceutical research 1991;8(2):278-81.
1991: Kimball P M; Kerman R H; Kahan B D
Failure of prolyl-peptidyl isomerase to mediate cyclosporine suppression of intracellular activation signal generation.
Transplantation 1991;51(2):509-13.
1991: Knight R J; Kerman R H; Welsh M; Golden D; Schoenberg L; Van Buren C T; Lewis R M; Kahan B D
Chronic rejection in primary renal allograft recipients under cyclosporine-prednisone immunosuppressive therapy.
Transplantation 1991;51(2):355-9.
1991: Kerman R H; Kimball P M; Van Buren C T; Lewis R M; DeVera V; Baghdahsarian V; Heydari A; Kahan B D
AHG and DTE/AHG procedure identification of crossmatch-appropriate donor-recipient pairings that result in improved graft survival.
Transplantation 1991;51(2):316-20.
1991: Kerman R H; Kimball P M; Van Buren C T; Lewis R M; DeVera V; Baghdahsarian V; Heydari A; Kahan B D
Improved renal allograft survival for AHG and DTE/AHG crossmatch-negative recipients.
Transplantation proceedings 1991;23(1 Pt 1):400-2.
1991: Kerman R H; Kimball P M; Van Buren C T; Lewis R M; Kahan B D
Stronger immune responsiveness of blacks vs whites may account for renal allograft survival differences.
Transplantation proceedings 1991;23(1 Pt 1):380-2.
1991: Kimball P M; Kerman R H; Kahan B D
Cyclosporine suppression of intracellular activation signal generation is not mediated by prolyl-peptidyl isomerase.
Transplantation proceedings 1991;23(1 Pt 1):323-4.
1991: Stepkowski S M; Goto S; Wiggins J; Christopher J; Kahan B D
Contribution of CD4+ cells to allorejection across a class I major histocompatibility complex barrier in congeneic rats.
Transplantation proceedings 1991;23(1 Pt 1):172-3.
1991: Kimball P M; Kerman R H; Kahan B D
Rapamycin and cyclosporine produce synergistic but nonidentical mechanisms of immunosuppression.
Transplantation proceedings 1991;23(1 Pt 2):1027-8.
1991: Kimball P M; Kerman R H; Kahan B D
Production of synergistic but nonidentical mechanisms of immunosuppression by rapamycin and cyclosporine.
Transplantation 1991;51(2):486-90.
1991: Katz S M; Kerman R H; Golden D; Grevel J; Camel S; Lewis R M; Van Buren C T; Kahan B D
Preemptive transplantation--an analysis of benefits and hazards in 85 cases.
Transplantation 1991;51(2):351-5.
1991: Kerman R H; Kimball P M; Van Buren C T; Lewis R M; Kahan B D
Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients.
Transplantation 1991;51(2):338-42.
1991: Kahan B D; Gibbons S; Tejpal N; Chou T C; Stepkowski S
Synergistic effect of the rapamycin-cyclosporine combination: median effect analysis of in vitro immune performances by human T lymphocytes in PHA, CD3, and MLR proliferative and cytotoxicity assays.
Transplantation proceedings 1991;23(1 Pt 2):1090-1.
1991: Goto S; Stepkowski S M; Kahan B D
Effect of FK 506 and cyclosporine on heart allograft survival in rats.
Transplantation proceedings 1991;23(1 Pt 1):529-30.
1991: Miyagawa S; Stepkowski S M; Kahan B D
Mechanism of unresponsiveness in rats induced by a short course of FK 506 or CyA.
Transplantation proceedings 1991;23(1 Pt 1):334-5.
1991: Kahan B D; Gibbons S; Tejpal N; Stepkowski S M; Chou T C
Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro.
Transplantation 1991;51(1):232-9.
1991: Stepkowski S M; Chen H; Daloze P; Kahan B D
Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat.
Transplantation 1991;51(1):22-6.
1991: Yoshimura N; Oka T; Kahan B D
Sequential determinations of serum interleukin 6 levels as an immunodiagnostic tool to differentiate rejection from nephrotoxicity in renal allograft recipients.
Transplantation 1991;51(1):172-6.
1991: Kahan B D
Transplantation timeline. Mankind's three millennia--one maverick's three decades in the struggle against biochemical individuality.
Transplantation 1991;51(1):1-21.
1990: Kahan B D; Shaw L M; Holt D; Grevel J; Johnston A
Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine.
Clinical chemistry 1990;36(8 Pt 1):1510-6.
1990: Citterio F; Chiocca A E; Kahan B D
Nuclear effects of cyclosporine.
Transplantation proceedings 1990;22(4):1742-3.
1990: Grevel J; Napoli K L; Kahan B D
Covariables in cyclosporine immunosuppression.
Transplantation proceedings 1990;22(3):1113-5.
1990: Kahan B D
Summary on therapeutic drug monitoring for renal transplantation.
Transplantation proceedings 1990;22(3):1348-51.
1990: Grevel J; Napoli K L; Kahan B D
Steady-state concentrations of cyclosporine for therapeutic monitoring.
Transplantation proceedings 1990;22(3):1339-42.
1990: Kahan B D; Napoli K; Welsh M; Grevel J; Rutzky L P
Comparison of the utility of 3H-based specific monoclonal antibody assay on whole blood samples with the fluorescence polarization nonspecific immunoassay on serum samples for diagnosis of adverse events in renal transplant patients.
Transplantation proceedings 1990;22(3):1274-9.
1990: Napoli K L; Kahan B D
Nonselective measurement of cyclosporine for therapeutic drug monitoring by fluorescence polarization immunoassay with a sheep polyclonal antibody: II. Evaluation of the whole blood methodology and comparison with an 3H tracer-mediated radioimmunoassay with a sheep polyclonal antibody.
Transplantation proceedings 1990;22(3):1181-5.
1990: Napoli K L; Kahan B D
Nonselective measurement of cyclosporine for therapeutic drug monitoring by fluorescence polarization immunoassay with a rabbit polyclonal antibody: I. Evaluation of the serum methodology and comparison with a sheep polyclonal antibody in an 3H-tracer mediated radioimmunoassay.
Transplantation proceedings 1990;22(3):1175-80.
1990: Kahan B D
The phoenix: symbol of rebirth and the eternal return.
Transplantation proceedings 1990;22(3):1097-103.
1990: Florence L S; Jiang G L; Ang K K; Stepkowski S M; Kahan B D
In vitro analysis of T cell-mediated cytotoxicity displayed by rat heart allograft recipients rendered unresponsive by total-lymphoid irradiation and extracted donor antigen.
Transplantation 1990;49(2):436-44.
1990: Roughneen P T; Kulkarni A D; Thompson D A; Kumar S; Van Buren C; Kahan B D; Rowlands B J
Temporal T cell suppression and impaired host responsiveness to nonvascularized neonatal cardiac allografts in experimental hepatic failure.
Transplantation proceedings 1990;22(1):291-3.
1990: Dunn J; Golden D; Van Buren C T; Lewis R M; Lawen J; Kahan B D
Causes of graft loss beyond two years in the cyclosporine era.
Transplantation 1990;49(2):349-53.
1990: Ito T; Stepkowski S M; Kahan B D
Soluble antigen and cyclosporine-induced specific unresponsiveness in rats. Frequency of alloantigen-specific T cytotoxic cells in normal, sensitized, and unresponsive rats.
Transplantation 1990;49(2):422-8.
1990: Vathsala A; Chou T C; Kahan B D
Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation.
Transplantation 1990;49(2):463-72.
1990: Grevel J; Napoli K L; Gibbons S; Kahan B D
Area-under-the-curve monitoring of cyclosporine therapy: performance of different assay methods and their target concentrations.
Therapeutic drug monitoring 1990;12(1):8-15.
1990: Kerman R H; Van Buren C T; Lewis R M; DeVera V; Baghdahsarian V; Gerolami K; Kahan B D
Improved graft survival for flow cytometry and antihuman globulin crossmatch-negative retransplant recipients.
Transplantation 1990;49(1):52-6.
1990: Vathsala A; Verani R; Schoenberg L; Lewis R M; Van Buren C T; Kerman R H; Kahan B D
Proteinuria in cyclosporine-treated renal transplant recipients.
Transplantation 1990;49(1):35-41.
1990: Dunn J; Grevel J; Napoli K; Lewis R M; Van Buren C T; Kahan B D
The impact of steady-state cyclosporine concentrations on renal allograft outcome.
Transplantation 1990;49(1):30-4.
1990: Kimball P M; Kerman R H; Kahan B D
Sensitivity of intracellular signals responsible for cell cycle progression to cyclosporine.
Transplantation 1990;49(1):186-91.
1989: Dunn J; Vathsala A; Golden D; Kerman R; Lawen J; Van Buren C T; Lewis R; Kahan B D
Impact of race on the outcome of renal transplantation under cyclosporine-prednisone.
Transplantation proceedings 1989;21(6):3946-8.
1989: Vathsala A; Weinberg R B; Schoenberg L; Grevel J; Dunn J; Goldstein R A; Van Buren C T; Lewis R M; Kahan B D
Lipid abnormalities in renal transplant recipients treated with cyclosporine.
Transplantation proceedings 1989;21(4):3670-3.
1989: Vathsala A; Weinberg R B; Schoenberg L; Grevel J; Goldstein R A; Van Buren C T; Lewis R M; Kahan B D
Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients.
Transplantation 1989;48(1):37-43.
1989: Kahan B D
Ganesha: the primeval Hindu xenograft.
Transplantation proceedings 1989;21(3 Suppl 1):1-8.
1989: Kahan B D
Pharmacokinetics and pharmacodynamics of cyclosporine.
Transplantation proceedings 1989;21(3 Suppl 1):9-15.
1989: Kahan B D
Case presentations in renal transplantation.
Transplantation proceedings 1989;21(3 Suppl 1):70-96.
1989: Kahan B D
Clinical problems in cyclosporine dosing with reference to clinical pharmacology: case histories and discussion.
Transplantation proceedings 1989;21(3 Suppl 1):16-40.
1989: Kahan B D
The impact of cyclosporine on the practice of renal transplantation.
Transplantation proceedings 1989;21(3 Suppl 1):63-9.
1989: Goto S; Stepkowski S M; Kahan B D
Multiple injections of KCl-extracted donor-antigen in combination with a short course of cyclosporine therapy induces prolonged heart allograft survival in rats.
Transplantation proceedings 1989;21(2):3300-2.
1989: Grevel J; Rigotti P; Citterio F; Plebani M; Kahan B D
The effect of end-to-side portacaval shunt on cyclosporine pharmacokinetics in rats.
Pharmaceutical research 1989;6(3):255-7.
1989: Grevel J; Reynolds K L; Rutzky L P; Kahan B D
Influence of demographic factors on cyclosporine pharmacokinetics in adult uremic patients.
Journal of clinical pharmacology 1989;29(3):261-6.
1989: Citterio F; Kahan B D
Specificity of the nuclear effect of cyclosporine on the immune cells.
Transplantation proceedings 1989;21(1 Pt 1):842-3.
1989: Lewis R M; Van Buren C T; Macris M; Frazier O H; Janney R P; McAndrew J; Kerman R H; Kahan B D
Evolution of renal function in cardiac vs. renal allograft recipients receiving long-term cyclosporine A (CsA) immunosuppressive therapy.
Transplantation proceedings 1989;21(1 Pt 2):1523-4.
1989: Citterio F; Kahan B D
Effects of cyclosporin on nuclear function of transplant recipient lymphocytes.
Transplantation proceedings 1989;21(1 Pt 2):1465-6.
1989: Smith A Y; Citterio F; Welsh M; Kerman R H; Kahan B D
Interleukin-2 receptor as an immunodiagnostic tool to differentiate rejection from nephrotoxicity.
Transplantation proceedings 1989;21(1 Pt 2):1462-4.
1989: Ito T; Stepkowski S M; Kahan B D
Decreased frequency of alloantigen-specific T cells following immunosuppression with extracted donor histocompatibility antigen and a brief course of cyclosporine.
Transplantation proceedings 1989;21(1 Pt 1):248-51.
1989: Stepkowski S; Goto S; Reynolds K; Ito T; Kahan B D
Induction of unresponsiveness after local low-dose cyclosporine administration.
Transplantation proceedings 1989;21(1 Pt 1):1120-2.
1989: Lewis R M; Janney R P; Golden D L; Kerr N B; Van Buren C T; Kerman R H; Kahan B D
Stability of renal allograft function associated with long-term cyclosporine immunosuppressive therapy--five year follow-up.
Transplantation 1989;47(2):266-72.
1989: Kahan B D; Kerman R H; Van Buren C T; Flechner S M; Golden D L; Lewis R M
Clinical outcome in 36 patients after at least one and up to 5 years of steroid withdrawal based upon specific mixed lymphocyte reaction hyporesponsiveness toward the living related donor.
Transplantation proceedings 1989;21(1 Pt 2):1579-80.
1989: Citterio F; Kahan B D
The inhibitory effect of cyclosporine on the nuclear proliferative response to a variety of T cell activators.
Transplantation 1989;47(2):334-8.
1989: Stepkowski S M; Goto S; Ito T; Reynolds K; Didlake R; Kim E K; Kahan B D
Prolongation of heterotopic heart allograft survival by local delivery of continuous low-dose cyclosporine therapy.
Transplantation 1989;47(1):17-23.
1989: Florence L S; Ito T; Ang K K; Jiang G L; Wong C S; Goto S; Didlake R; Kim E K; Stepkowski S; Kahan B D
The synergistic effect of total-lymphoid irradiation with extracted donor alloantigen in inducing transplantation unresponsiveness.
Transplantation 1989;47(1):156-62.
1989: Roesel T; LeGrue S J; Liehr J; Kahan B D
Isolation and in vitro characterization of a novel immunosuppressive cyclosporine metabolite.
Transplantation 1989;47(1):149-56.
1989: Grevel J; Welsh M S; Kahan B D
Cyclosporine monitoring in renal transplantation: area under the curve monitoring is superior to trough-level monitoring.
Therapeutic drug monitoring 1989;11(3):246-8.
1988: Didlake R; Kim E K; Kahan B D
Ability of 3M KC1-extracted histocompatibility antigen to potentiate the immunosuppressive effect of cyclosporine to prolong the survival of heterotopic rat cardiac allografts.
Transplantation 1988;46(5):743-7.
1988: Kahan B D; Grevel J
Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy.
Transplantation 1988;46(5):631-44.
1988: Didlake R H; Dreyfus K; Kerman R H; Van Buren C T; Kahan B D
Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants.
Transplantation proceedings 1988;20(3 Suppl 3):63-9.
1988: Lewis R M; Janney R P; Van Buren C T; Kerman R H; Herson J; Kerr N A; Golden D A; Kahan B D
A retrospective analysis of long-term renal allograft function associated with cyclosporine-prednisone immunosuppressive therapy.
Transplantation proceedings 1988;20(3 Suppl 3):534-9.
1988: Kahan B D
Renal transplantation.
Transplantation proceedings 1988;20(3 Suppl 3):297-310.
1988: Conley S B; Portman R J; Lemire J M; Van Buren C T; Lewis R; Kahan B D
Five years' experience with cyclosporine in children.
Transplantation proceedings 1988;20(3 Suppl 3):280-4.
1988: Kerman R H; Van Buren C T; Lewis R M; Kahan B D
Impact of blood transfusions and HLA on cyclosporine-treated renal transplant recipients.
Transplantation proceedings 1988;20(3 Suppl 3):264-9.
1988: Smith A Y; Kerman R H; Van Buren C T; Lewis R M; Kahan B D
Pediatric cadaveric kidneys in recipients treated with cyclosporine.
Transplantation proceedings 1988;20(3 Suppl 3):215-21.
1988: Smith A Y; Van Buren C T; Lewis R M; Kerman R H; Welsh M; Kahan B D
The outcome of repeat cadaveric kidney transplants in recipients managed with cyclosporine.
Transplantation proceedings 1988;20(3 Suppl 3):180-93.
1988: Ito T; Stepkowski S; Kahan B D
Frequency of T cytotoxic cells after perioperative treatment with extracted antigen and cyclosporine in rat cardiac transplantation.
Transplantation proceedings 1988;20(3 Suppl 3):1045-52.
1988: Kahan B D; Didlake R; Kim E E; Yoshimura N; Kondo E; Stepkowski S
Important role of cyclosporine for the induction of immunologic tolerance in adult hosts.
Transplantation proceedings 1988;20(3 Suppl 3):23-35.
1988: Didlake R H; Kim E K; Kahan B D
Impact of a combined regimen of cyclosporine and 3M KCl extracted histocompatibility antigen on heterotopic rat cardiac allograft survival.
Transplantation proceedings 1988;20(3 Suppl 3):1034-7.
1988: Citterio F; Kahan B D
Effects of cyclosporine on nuclear function.
Transplantation proceedings 1988;20(2 Suppl 2):75-9.
1988: Reynolds K L; Grevel J; Gibbons S Y; Welsh M S; Rutzky L P; Kahan B D
Cyclosporine pharmacokinetics in uremic patients: influence of different assay methods.
Transplantation proceedings 1988;20(2 Suppl 2):462-5.
1988: Gibbons S; Grevel J; Reynolds K; Ried M; Rutzky L P; Kahan B D
Comparison and correlation of assays for monitoring cyclosporine drug levels in renal transplant recipients.
Transplantation proceedings 1988;20(2 Suppl 2):339-44.
1988: Kahan B D
Pien Ch'iao, the legendary exchange of hearts, traditional Chinese medicine, and the modern era of cyclosporine.
Transplantation proceedings 1988;20(2 Suppl 2):2-12.
1988: Didlake R H; Kim E K; Grevel J; Jarolimek L; Kahan B D
Cyclosporine pharmacokinetics and pharmacodynamics after oral administration in the rat.
Transplantation proceedings 1988;20(2 Suppl 2):692-5.
1988: Kahan B D; Didlake R; Kim E E; Yoshimura N; Kondo E; Stepkowski S
Important role of cyclosporine for the induction of immunologic tolerance in adult hosts.
Transplantation proceedings 1988;20(2 Suppl 2):438-50.
1988: Kakizaki K; Basadonna G; Kahan B; Merrell R
Cyclosporine absorption in apancreatic dogs.
American journal of surgery 1988;155(3):467-9.
1988: Smith A Y; Van Buren C T; Lewis R M; Kerman R H; Kahan B D
Short-term and long-term function of cadaveric kidneys from pediatric donors in recipients treated with cyclosporine.
Transplantation 1988;45(2):360-7.
1988: Kerman R H; van Buren C T; Lewis R M; Frazier O H; Cooley D; Kahan B D
The impact of HLA A, B, and DR blood transfusions and immune responder status on cardiac allograft recipients treated with cyclosporine.
Transplantation 1988;45(2):333-7.
1988: Lewis R M; Johnson P C; Golden D; Van Buren C T; Kerman R H; Kahan B D
The adverse impact of cytomegalovirus infection on clinical outcome in cyclosporine-prednisone treated renal allograft recipients.
Transplantation 1988;45(2):353-9.
1988: Kerman R H; Van Buren C T; Lewis R M; Kahan B D
Successful transplantation of 100 untransfused cyclosporine-treated primary recipients of cadaveric renal allografts.
Transplantation 1988;45(1):37-40.
1988: Colon R; Frazier O H; Kahan B D; Radovancevic B; Duncan J M; Lorber M I; Van Buren C T
Complications in cardiac transplant patients requiring general surgery.
Surgery 1988;103(1):32-8.
1988: Naito K; Pellis N R; Kahan B D
Active specific immunotherapy with extracted tumor-specific transplantation antigen, cyclophosphamide, and adoptive transfer of tumor-specific cytotoxic T-cell clones.
Cellular immunology 1988;111(1):216-34.
1988: Naito K; Pellis N R; Kahan B D
Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
Cancer research 1988;48(1):101-8.
1988: Didlake R H; Kim E K; Sheehan K; Schreiber R D; Kahan B D
Effect of combined anti-gamma interferon antibody and cyclosporine therapy on cardiac allograft survival in the rat.
Transplantation 1988;45(1):222-3.
1988: Johnson P C; Lewis R M; Golden D L; Oefinger P E; Van Buren C T; Kerman R H; Kahan B D
The impact of cytomegalovirus infection on seronegative recipients of seropositive donor kidneys versus seropositive recipients treated with cyclosporine-prednisone immunosuppression.
Transplantation 1988;45(1):116-21.
1988: Kerman R H; Van Buren C T; Lewis R M; Kahan B D
Blood transfusion experience for cyclosporine/prednisone-treated renal allograft recipients at the University of Texas Medical School at Houston.
Clinical transplants 1988;():167-70.
1987: Kahan B D; Conley S; Portman R; Lemaire R; Wideman C; Flechner S; Van Buren C
Parent-to-child transplantation with cyclosporine immunosuppression.
The Journal of pediatrics 1987;111(6 Pt 2):1012-6.
1987: Jarowenko M V; Flechner S M; Van Buren C T; Lorber M I; Kahan B D
Influence of cyclosporine on posttransplant blood pressure response.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1987;10(2):98-103.
1987: Kahan B D
Cyclosporin as an adjunct to the induction of specific unresponsiveness.
Annales de l'Institut Pasteur. Immunology 1987;138(4):618-21.
1987: Roughneen P T; Didlake R; Kumar S C; Kahan B D; Rowlands B J
The protective effect of hepatic dysfunction on vascularized allograft survival.
The Journal of surgical research 1987;42(5):447-53.
1987: Kakizaki K; Didlake R; Basadonna G; Kahan B D; Merrell R C
Donor-specific antigen and cyclosporine in rat islet allografts.
The Journal of surgical research 1987;42(5):494-7.
1987: Roughneen P T; Didlake R; Kumar S C; Kahan B D; Rowlands B J
Enhancement of heterotopic cardiac allograft survival by experimental biliary ligation.
Transplantation 1987;43(3):437-8.
1987: Lorber M I; Van Buren C T; Flechner S M; Williams C; Kahan B D
Hepatobiliary complications of cyclosporine therapy following renal transplantation.
Transplantation proceedings 1987;19(1 Pt 2):1808-10.
1987: Lorber M I; Van Buren C T; Flechner S M; Cameron L; Leatherwood J; Walker W E; Smalling R W; Kahan B D
Pretransplant coronary arteriography for diabetic renal transplant recipients.
Transplantation proceedings 1987;19(1 Pt 2):1539-41.
1987: Didlake R; Kakazaki K; Yoshimura N; Merrell R; Kahan B D
Effects of a combined antigen-cyclosporine regimen in four transplantation models.
Transplantation proceedings 1987;19(1 Pt 2):1281-3.
1987: Burstain T L; Frazier O H; Schnee M J; Kerman R H; Lorber M I; Cooley D A; Radovancevic B; Colon R; McAllister H; Kahan B D
Predictors of rejection in cyclosporine-treated cardiac allograft recipients.
Transplantation proceedings 1987;19(1 Pt 3):2531-3.
1987: Smith A Y; Van Buren C T; Lewis R M; Kerman R H; Kahan B D
Factors determining renal transplant outcome at the University of Texas at Houston.
Clinical transplants 1987;():155-66.
1986: Jarowenko M V; Van Buren C T; Kramer W G; Lorber M I; Flechner S M; Kahan B D
Ranitidine, cimetidine, and the cyclosporine-treated recipient.
Transplantation 1986;42(3):311-2.
1985: Kahan B D; Kerman R H; Wideman C A; Flechner S M; Jarowenko M; Van Buren C T
Impact of cyclosporine on renal transplant practice at the University of Texas Medical School at Houston.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1985;5(6):288-95.
1985: Jarowenko M V; Flechner S M; Sandler C M; Van Buren C T; Kahan B D
Salvage of difficult transplant complications by percutaneous techniques.
The Journal of urology 1985;133(5):840-3.
1985: Kahan B D; van Buren C T; Flechner S M; Jarowenko M; Yasumura T; Rogers A J; Yoshimura N; LeGrue S; Drath D; Kerman R H
Clinical and experimental studies with cyclosporine in renal transplantation.
Surgery 1985;97(2):125-40.
1984: Van Buren D; Wideman C A; Ried M; Gibbons S; Van Buren C T; Jarowenko M; Flechner S M; Frazier O H; Cooley D A; Kahan B D
The antagonistic effect of rifampin upon cyclosporine bioavailability.
Transplantation proceedings 1984;16(6):1642-5.
1984: Kahan B D; Wideman C; Gibbons S; Ried M; Jarowenko M; Flechner S; Van Buren C T
Impact of mode of pretransplant loading with cyclosporine on the incidence of early rejection in haploidentical living related donor renal recipients.
Transplantation proceedings 1984;16(6):1619-23.
1984: Kahan B D; Wideman C A; Reid M; Gibbons S; Jarowenko M; Flechner S; Van Buren C T
The value of serial serum trough cyclosporine levels in human renal transplantation.
Transplantation proceedings 1984;16(5):1195-9.
1984: Kahan B D; Wideman C A; Flechner S; Van Buren C T
Anaphylactic reaction to intravenous cyclosporin.
Lancet 1984;1(8367):52.
1983: Kahan B D; Van Buren C T; Boileau M; Ried M; Payne W D; Flechner S; Newburger J
Cyclosporin A tissue levels in a cadaveric renal allograft recipient.
Transplantation 1983;35(1):96-9.

Sign-in to see more